AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027

Loading news article.

AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027 | WAPE

AIM ImmunoTech Doses Final Patient In Phase 2 Trial Of Ampligen For Treatment Of Metastatic Pancreatic Cancer In Combination With AstraZeneca's Imfinzi; Topline Results Expected Q1 2027

Article summary

Related companies

Comments —